BIND Therapeutics, a Cambridge nanomedicine company developing programmable drugs, said Monday that it has dosed the first patient in a Phase 2 clinical trial of BIND-014 as a second-line therapy in patients with non-small cell lung cancer. The company is using a nano-engineering platform to develop Accurins, programmable therapeutics designed to target specific cells or tissues and concentrate …Source:
http://feeds.boston.com/c/35022/f/646890/s/3032f57c/sc/14/l/0L0Sboston0N0Cbusiness0Cinnovation0Cblogs0Cinside0Ethe0Ehive0C20A130C0A70C290Cbind0Edoses0Efirst0Epatient0Estudy0Edrug0Efor0Enon0Esmall0Ecell0Elung0Ecancer0CBBX1PALIUoDcyRdgskPuxN0Cblog0Bhtml0Drss0Iid0FMost0KPopular/story01.htm
↧
BIND doses first patient in a study of a drug for non-small cell lung cancer – Boston.com
↧